Immunovant Inc. IMVT
$33.29
▲ +2.25% 24H
About
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Headquartered in Durham, North Carolina and founded in 2018, the company specializes in immunology and leverages anti-FcRn (neonatal Fc receptor) technology to modulate immunoglobulin G (IgG) levels in…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees315
TickerIMVT
Statistics
Market Cap$6.79B
Revenue (TTM)—
Net Income-$505.6M
Net Margin—
EPS$-2.77
P/E—
P/S—
P/B7.51
EV/EBITDA-10.49
ROE-64.8%
Dividend Yield—
Price$33.29
Data: Twelve Data · Revenue = mcap / P/S